Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma

Trial Profile

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2018

At a glance

  • Drugs LN 145 (Primary)
  • Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Iovance Biotherapeutics
  • Most Recent Events

    • 06 Nov 2018 According to an Iovance Biotherapeutics media release, the company anticipates providing an update on this study at an upcoming medical meeting in 2019.
    • 06 Nov 2018 According to an Iovance Biotherapeutics media release, the protocol for this study has been amended to limit the number of prior therapies to no more than three and to exclude patients who have been treated with prior immunotherapy.
    • 11 Oct 2018 According to an Iovance Biotherapeutics media release, patient dosing has been initiated in Europe. Stage one of the study has now been completed and enrollment in the study continues.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top